| EPB151 | A pilot study of the impact of a rapid ART initiation in advanced HIV disease | E-poster | ART in acute, first- and second-line therapies |
| EPB152 | Country of birth influences INSTI prescription in treatment-naive patients living with HIV in France | E-poster | ART in acute, first- and second-line therapies |
| EPB153 | Starting antiretroviral therapy (ART) at the first HIV-specialist appointment with or without baseline laboratory data with BIC/FTC/TAF (The BIFAST study) | E-poster | ART in acute, first- and second-line therapies |
| EPB154 | Doravirine associated resistance mutations in antiretroviral therapy naïve and experienced HIV-1C infected people in Botswana | E-poster | ART in highly treatment-experienced persons |
| EPB155 | The presence of minority HIV Drug resistance variants in the protease and Gag regions confers poor response to therapy among subtype A and D patients | E-poster | ART in highly treatment-experienced persons |
| EPB156 | How clinical trials of combination antiretroviral therapy for adults with HIV capture health-related quality of life with patient-reported measures: a systematic review | E-poster | ART in highly treatment-experienced persons |
| EPB157 | Comparison of virologic suppression rates among first- and second-line antiretroviral therapy patients at an urban clinic in Zimbabwe: a cohort study | E-poster | ART in highly treatment-experienced persons |
| EPB158 | Low level of virologic failure and resistance in ART-experienced, integrase inhibitor-naïve participants receiving dolutegravir (DTG) and Nucleoside Reverse Transcriptase Inhibitors (NRTIs) combined regimens: 10-year follow-up in the SAILING Study | E-poster | ART in highly treatment-experienced persons |
| EPB159 | Safety and efficacy of switching to BIC/FTC/TAF plus DOR in HIV-infected patients with multiclass-resistant virus | E-poster | ART in highly treatment-experienced persons |
| EPB160 | Efficacy and safety of fostemsavir plus optimized background therapy in heavily treatment-experienced adults with HIV-1: week 240 results of the Phase 3 BRIGHTE study | E-poster | ART in highly treatment-experienced persons |